Thursday, April 24, 2014

Venaxis prices $20-million equity offering

Venaxis prices $20-million equity offering

April 3, 2014 by · Leave a Comment 

Tweet Venaxis (NASDAQ:APPY) has priced a public offering of 8,335,000 common shares at a price of $2.40 each and given underwriters a 30-day option to purchase up to an additional 1,250,250 shares to cover over-allotments, if any. Net proceeds are expected to be approximately $18.4-million. Proceeds will be used for working capital and other general corporate […]

Canaccord cuts Sunshine Heart target to $10

Canaccord cuts Sunshine Heart target to $10

March 11, 2014 by · Leave a Comment 

Tweet Canaccord Genuity has lowered its price target for “buy-rated” Sunshine Heart (NASDAQ:SSH) to $10 from $14.75, reflecting more conservative out-year revenue targets. The stock was quoted at $6.34, down 21%, on Tuesday afternoon. Analyst Jason Mills writes cites a corporate update that “served as a reminder that the company is still in the early […]

Aurinia in record US$52-million Canadian PIPE

Aurinia in record US$52-million Canadian PIPE

February 14, 2014 by · Leave a Comment 

Tweet Aurinia Pharmaceuticals (TSX-V:AUP) has completed the largest traditional PIPE (private investment in public equity) financing by a life sciences company in Canadian history.  Under the terms of the offering, Aurinia issued 18,919,404 units at a subscription price of US$2.7485 (C$3.038) per unit.  Each unit consisted of one common share and one-quarter of a common […]

Venaxis pivotal APPY1 data due in March

Venaxis pivotal APPY1 data due in March

February 4, 2014 by · Leave a Comment 

Tweet Venaxis (NASDAQ:APPY) expects to report top-line data in March from a pivotal study of its rapid, protein biomarker-based assay for appendicitis, the APPY1 Test and, depending on the results, submit a final data package to the FDA soon after. “We continue to have very positive dialogue with emergency room physicians and administrators at leading hospitals in the […]

Canaccord ups Transition to speculative buy

Canaccord ups Transition to speculative buy

December 10, 2013 by · Leave a Comment 

Tweet Canaccord Genuity has upgraded Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) to “speculative buy” from “hold” and raised its price target to $9.80 from $4.75. The stock closed at $5.86 on the TSX on Monday. “We have taken a closer look at [Transition’s] ELND-005 after attending the Clinical Trials on Alzheimer’s Disease (AD) conference and recently having […]

Canaccord cuts Oncolytics price target

Canaccord cuts Oncolytics price target

November 22, 2013 by · Leave a Comment 

Tweet Canaccord Genuity has lowered its price target for “buy-rated” Oncolytics Biotech (NASDAQ:ONCY; TSX:ONC) to $6.50 from $8 after the company reported top-line head and neck cancer data that raised “more questions than answers.” Analyst Neil Maruoka writes that while the company reported positive median progression free survival for its Reolysin drug candidate, “limited detail, […]

Canaccord ups Novadaq target to $22

Canaccord ups Novadaq target to $22

October 23, 2013 by · Leave a Comment 

Tweet Canaccord Genuity has raised its price target for “buy-rated” Novadaq Technologies (NASDAQ:NVDQ; TSX;NDQ) to $22 from $18 after the company’s third quarter report beat consensus estimates. The stock closed at $16.18 on Tuesday. “We continue to believe that Novadaq possesses one of the most attractive, emerging technologies in med-tech, and possesses the largest, least-penetrated […]

Isotechnika, Aurinia complete merger, financing

Isotechnika, Aurinia complete merger, financing

September 23, 2013 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) and Aurinia Pharmaceuticals have completed their merger and will operate under the name, Aurinia Pharmaceuticals. The transaction was approved by shareholders on Aug. 15. In connection with the merger, the company has completed, subject to regulatory approval, a private placement of 133,333,332 units, consisting of one common share and one half […]

TearLab Q2 gets high marks from analysts

TearLab Q2 gets high marks from analysts

August 15, 2013 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) received widespread support from analysts after the company’s conference call on Tuesday evening, which included a panel discussion with four eye care professionals who use the TearLab Osmolarity System in their businesses. Feltl & Co. analyst Ben Haynor, who has raised his price target to $17 from $15 and reiterated his […]

Craig-Hallum, Canaccord up TearLab price targets

Craig-Hallum, Canaccord up TearLab price targets

August 6, 2013 by · Leave a Comment 

Tweet Craig-Hallum Capital Group and Canaccord Genuity raised their price targets for “buy-rated” TearLab (NASDAQ:TEAR; TSX:TLB) after the company pre-announced second quarter revenues and system order numbers and completed a $40.4-million equity offering. Shares of TearLab closed at $12.75 on Monday. “We believe the bigger story in the second quarter relates to the signing of […]

Next Page »

Google+